Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab biosimilar - Amgen

Next Previous
X
Search
Drug Profile

Pembrolizumab biosimilar - Amgen

Alternative Names: ABP-234

Latest Information Update: 11 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 12 Sep 2024 Phase-III clinical trials in Non-small cell lung cancer (Early-stage disease, Adjuvant therapy) in Bulgaria, Poland, Spain, Serbia, Italy, Chile (IV) (NCT06430866)
  • 31 May 2024 Amgen plans a phase III trial for Non small cell lung cancer (Adjuvant treatment) (IV, Injection) in July 2024 (NCT06430866)
  • 19 Mar 2024 Amgen plans a phase III trial for Non-Small Cell Lung Cancer (Late-stage disease, Metastatic disease, First line therapy) in March 2024 (IV) (NCT06311721) .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top